JP2013533227A5 - - Google Patents

Download PDF

Info

Publication number
JP2013533227A5
JP2013533227A5 JP2013513645A JP2013513645A JP2013533227A5 JP 2013533227 A5 JP2013533227 A5 JP 2013533227A5 JP 2013513645 A JP2013513645 A JP 2013513645A JP 2013513645 A JP2013513645 A JP 2013513645A JP 2013533227 A5 JP2013533227 A5 JP 2013533227A5
Authority
JP
Japan
Prior art keywords
ethoxy
fgf21
acetylamino
des181
conh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013513645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013533227A (ja
Filing date
Publication date
Priority claimed from PCT/EP2010/057986 external-priority patent/WO2010142665A1/en
Application filed filed Critical
Priority claimed from PCT/EP2011/059273 external-priority patent/WO2011154349A2/en
Publication of JP2013533227A publication Critical patent/JP2013533227A/ja
Publication of JP2013533227A5 publication Critical patent/JP2013533227A5/ja
Withdrawn legal-status Critical Current

Links

JP2013513645A 2010-06-08 2011-06-06 Ｆｇｆ２１類似体および誘導体 Withdrawn JP2013533227A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EPPCT/EP2010/057986 2010-06-08
PCT/EP2010/057986 WO2010142665A1 (en) 2009-06-11 2010-06-08 Glp-1 and fgf21 combinations for treatment of diabetes type 2
CN2010001099 2010-07-21
CN2010/001099 2010-07-21
US37329010P 2010-08-13 2010-08-13
US61/373,290 2010-08-13
PCT/EP2011/059273 WO2011154349A2 (en) 2010-06-08 2011-06-06 Fgf21 analogues and derivatives

Publications (2)

Publication Number Publication Date
JP2013533227A JP2013533227A (ja) 2013-08-22
JP2013533227A5 true JP2013533227A5 (enExample) 2014-07-24

Family

ID=99797984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013513645A Withdrawn JP2013533227A (ja) 2010-06-08 2011-06-06 Ｆｇｆ２１類似体および誘導体

Country Status (3)

Country Link
EP (1) EP2579889A2 (enExample)
JP (1) JP2013533227A (enExample)
WO (1) WO2011154349A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
AU2013274639A1 (en) * 2012-06-11 2014-11-06 Eli Lilly And Company Fibroblast growth factor 21 variants
TWI513705B (zh) * 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
EP3798228A1 (en) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
WO2015103782A1 (en) * 2014-01-13 2015-07-16 Wenzhou Medical College Biological Pharmaceuticals And Nature Products Ltd., Co Fgf21 mutant and conjugate thereof
RS60593B1 (sr) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
WO2015138278A1 (en) 2014-03-11 2015-09-17 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
SG11201702757YA (en) 2014-10-23 2017-05-30 Ngm Biopharmaceuticals Inc Pharmaceutical compositions comprising peptide variants and methods of use thereof
MX2017004947A (es) 2014-10-24 2017-06-29 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
RS59154B1 (sr) 2014-12-23 2019-10-31 Novo Nordisk As Fgf21 derivati i njihova upotreba
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
US20190142963A1 (en) 2016-04-15 2019-05-16 Richard D. DiMarchi Fgf21 c-terminal peptide optimization
EP3463427A4 (en) * 2016-05-25 2020-03-11 Board of Regents, The University of Texas System METHOD AND COMPOSITIONS FOR TREATING SECRETORIC DISEASES
WO2017220706A1 (en) 2016-06-22 2017-12-28 Novo Nordisk A/S Pharmaceutical compositions of fgf21 derivatives and uses thereof
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN108619490A (zh) * 2017-03-22 2018-10-09 天士力医药集团股份有限公司 一种长效化突变的人源成纤维生长因子的新用途
CN110709520B (zh) 2017-04-21 2024-04-05 株式会社柳韩洋行 用于产生双功能蛋白质及其衍生物的方法
CN111050786A (zh) 2017-09-08 2020-04-21 百时美施贵宝公司 用于治疗非酒精性脂肪性肝炎(nash)的方法的修饰的成纤维细胞生长因子21(fgf-21)
WO2019123427A1 (en) 2017-12-22 2019-06-27 Novartis Ag Methods of treating metabolic disorders with fgf21 variants
KR20210027426A (ko) 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 Fgf21 제제
EP3819307A1 (en) 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
US20220016211A1 (en) 2020-01-08 2022-01-20 Bristol-Myers Squibb Company Fgf-21 conjugate formulations
WO2022032187A1 (en) 2020-08-07 2022-02-10 Bristol-Myers Squibb Company Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
WO2022115597A1 (en) 2020-11-25 2022-06-02 Bristol-Myers Squibb Company Methods of treating liver diseases
US20240279297A1 (en) * 2021-05-11 2024-08-22 Cytoki Pharma Aps Therapeutic derivatives of interleukin-22
JP2024531980A (ja) 2021-09-08 2024-09-03 リートー ラボラトリーズ カンパニー リミテッド Ｆｇｆ２１変異タンパク質及びその応用
JP2025518285A (ja) 2022-06-03 2025-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄由来増殖因子の組換え発現
WO2025073372A1 (en) 2023-10-05 2025-04-10 Boehringer Ingelheim International Gmbh Recombinant expression of myeloid-derived growth factor
TW202539726A (zh) 2023-12-06 2025-10-16 德商百靈佳殷格翰國際股份有限公司 包含骨髓衍生性生長因子之新穎調配物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032678A1 (en) 1999-11-05 2001-05-10 Smithkline Beecham Corporation sbgFGF-19a
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
EP1329227A1 (en) 2002-01-22 2003-07-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells
WO2005091944A2 (en) 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
PL1751184T3 (pl) 2004-05-13 2010-02-26 Lilly Co Eli Białka fuzyjne FGF-21
EP1789443A1 (en) 2004-09-02 2007-05-30 Eli Lilly And Company Muteins of fibroblast growth factor 21
BRPI0514790A (pt) 2004-09-02 2008-06-24 Lilly Co Eli muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano
JP2008522617A (ja) 2004-12-14 2008-07-03 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
EP1846019A2 (en) 2005-01-21 2007-10-24 Eli Lilly And Company Method for treating cardiovascular disease
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
US20110034373A1 (en) * 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
US20100261637A1 (en) * 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
NZ592009A (en) * 2008-10-10 2012-11-30 Amgen Inc Fgf21 mutants and uses thereof
WO2010065439A1 (en) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
CN102361647B (zh) * 2009-01-23 2018-02-16 诺沃-诺迪斯克有限公司 具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用
CN102802657A (zh) * 2009-06-11 2012-11-28 诺沃-诺迪斯克有限公司 用于治疗2型糖尿病的glp-1和fgf21组合

Similar Documents

Publication Publication Date Title
BR112014003225A2 (pt) profármacos de treprostinil ligados a veículo
JP2013532644A5 (enExample)
JP2017500289A5 (enExample)
JP2012529463A5 (enExample)
HRP20181026T1 (hr) Dugodjelujuće formulacije inzulina
MY174002A (en) Combination theraphy for the treatment of diabetes
UA114700C2 (uk) Тверда фармацевтична форма для перорального застосування та процес її виготовлення
JP2013530974A5 (enExample)
HRP20140480T1 (hr) Pegilirani spojevi inzulina lispro
EP2390265A3 (en) Insulinotropic peptide derivative wherein its N-terminal amino acid is modified
WO2009033770A3 (en) Calcitonin c-terminal flanking peptide for use as a therapeutic agent
WO2009043466A3 (en) Therapeutic use of the peptide gluten exorphin a5
RU2016135543A (ru) Новые производные инсулина и их применение в медицине
WO2009033792A3 (en) Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
WO2009039985A3 (en) Therapeutic uses of urocortin ii
JP2018527288A5 (enExample)
ATE520406T1 (de) Kristalline form des ibandronat-natriums
WO2009046822A3 (en) Use of the peptide ymdgtmsqv as a therapeutic agent
WO2009033712A3 (en) Use of melanotan ii as a therapeutic agent
JP2017508741A5 (enExample)
JP2011046708A5 (enExample)
WO2009046858A3 (en) Therapeutic uses of kisspeptin 13 and compositions thereof
MX350195B (es) Analogos de cistamina para el tratamiento de la enfermedad de parkinson.
JP2011518176A5 (enExample)